European Medicines Agency recommends granting marketing authorisation for cinacalcet mylan

On 24 September 2015, the European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product cinacalcet (Cinacalcet Mylan), intended for the treatment of secondary hyperparathyroidism and reduction of hypercalcaemia in patients with parathyroid carcinoma. Read more here